The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma

Clinical trial NCT05827770 · UNKNOWN

Trial details

NCT number: NCT05827770
Sponsor: Yong Chen
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Stage III

Start date: 2023-05-01
Primary completion: 2024-12-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.